|
|
Phase III Randomized Study of Risedronate For Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy For Primary Breast Cancer
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Registry Information
Alternate Title
Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Supportive care
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
NCCTG-N02C1 N02C1, NCT00054418
|
|
|
Objectives - Compare the effectiveness of risedronate vs placebo in the prevention of bone loss in premenopausal women undergoing adjuvant or neoadjuvant chemotherapy for primary breast cancer.
- Compare the degree of bone loss over 1 year in these women according to menopausal status after 1 year of therapy.
- Determine the relationship of current climacteric symptoms, menstrual and reproductive history, and chemotherapy regimen with ovarian failure (permanent cessation of menses) in these women.
- Determine the relationship of baseline serum estradiol levels with ovarian failure in these women.
Entry Criteria Disease Characteristics:
- Resectable primary breast cancer
- Scheduled to undergo adjuvant or neoadjuvant chemotherapy
- No hypercalcemia (calcium level greater than 1 mg/dL above upper limit of normal within the past 6 months)
- No hypocalcemia (calcium level greater than 0.5 mg/dL below lower limit of normal within the past 6 months)
- No diseases affecting bone metabolism (i.e., hyperparathyroidism, hyperthyroidism, and hypercortisolism)
- Bone mineral density T score of -2.0 or greater at the hip or spine (T score of -2.1 or less is ineligible)
Prior/Concurrent Therapy:
Biologic therapy Chemotherapy - See Disease Characteristics
Endocrine therapy - No concurrent estrogen
- No concurrent estrogen receptor modulators except tamoxifen
- No corticosteroid dose of prednisone or equivalent greater than 5 mg daily for more than 2 weeks within the past 6 months
- No concurrent estrogen replacement therapy
- No concurrent oral contraceptives
Radiotherapy Surgery - More than 3 months since prior and no concurrent dental extraction, root canal, or dental implants
- No prior bilateral oophorectomy
Other - No prior bisphosphonates
- No other concurrent bisphosphonates
Patient Characteristics:
Age Sex Menopausal status - Premenopausal meeting the following criteria:
- No more than 6 months since last menstrual period
- No prior bilateral oophorectomy
- Not on estrogen replacement therapy
- If total abdominal hysterectomy performed, then must have at least 1 intact ovary
- If more than 3 months since last menstrual period, then must have premenopausal estrogen levels within 1 month of study entry
Performance status Life expectancy Hematopoietic Hepatic Renal - Creatinine no greater than 2.0 mg/dL
- No history of severe renal impairment
Other - Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective barrier contraception
- Able to stand or sit upright for at least 30 minutes
- No known swallowing disorder
- No history of vertebral compression fracture
- Traumatic fracture of the coccyx allowed
- No malabsorption syndrome
Expected Enrollment A total of 220 patients (110 per treatment arm) will be accrued for this study within 11 months. Outcomes Primary Outcome(s)Average intra-patient change in lumbar spine (L2-L4, PA) bone
mineral density (BMD) from baseline to one year after study
entry
Secondary Outcome(s)Average intra-patient change in femoral neck and total hip BMD from
baseline to one year after study entry Incidence of osteopenia in the risedronate vs placebo groups at one
year after study entry Incidence of osteoporosis in the risedronate vs placebo groups at one
year after study entry Incidence of a 5% difference in intra-patient BMD scores at baseline Serum and urine N-telopeptide and serum alkaline phosphatase at baseline
and 6 months Frequency and severity of toxicity as measured by NCI CTC version 2.0 Menopausal symptoms as measured by the Greene Climacteric Scale (GCS) at baseline, monthly during chemotherapy, at 6 months, 1 year,
and 2 years after study entry Association of baseline serum estradiol levels with permanent cessation of
menses Relationship between the subscales of the GCS
(psychological, vasomotor, somatic and sexual) with type of chemotherapy,
duration of chemotherapy, and menstrual cycle changes
Outline This is a randomized, placebo-controlled, double-blind study. Patients are stratified according to planned tamoxifen therapy (yes vs no vs undecided), planned taxane therapy (yes vs no vs undecided), time from last menses (1-3 months vs longer than 3 months to 6 months), and age (under 40 vs 40 to 49 vs 50 and over). Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive oral calcium and oral cholecalciferol daily and oral risedronate once weekly.
- Arm II: Patients receive calcium and cholecalciferol as in arm I and oral placebo once weekly.
In both arms, treatment begins during the first month of chemotherapy and continues for 1 year in the absence of unacceptable toxicity. Questionnaires about cessation of menses, ovarian failure, and menopausal symptoms are completed at baseline, monthly during chemotherapy, at 6 months, and then at 1 and 2 years. Patients are followed for 1 year.
Trial Contact Information
Trial Lead Organizations North Central Cancer Treatment Group | | | Stephanie Hines, MD, Protocol chair | | | |
Registry Information | | Official Title | | A Phase III Randomized, Placebo-Controlled, Double-Blind Trial Of Risedronate (Actonel) For Prevention Of Bone Loss In Premenopausal Women Undergoing Chemotherapy For Primary Breast Carcinoma | | Trial Start Date | | 2003-03-21 | | Registered in ClinicalTrials.gov | | NCT00054418 | | Date Submitted to PDQ | | 2002-12-31 | | Information Last Verified | | 2006-05-21 | | NCI Grant/Contract Number | | CA25224 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|